Sai Parenterals Q1 FY27: Building a Regulated Market Platform While Rewiring the Capex Plan

Sai Parenterals entered FY27 as a larger consolidated group after the addition of Noumed Pharmaceuticals, and Q1 FY27 was only the second quarter of reporting on this expanded base. Consolidated revenue for the quarter was ₹182 crore, EBITDA was ₹27.3 crore at a margin of 14.9%, and PAT was ₹7.9 crore at a margin of 4.3%. Management highlighted that Q1 FY27 includes a full quarter of Noumed, while Q1 FY26 includes none, so year on year comparisons are not like for like.

The quarter was positioned as a steady start to a year that is structurally second half weighted. Management reiterated FY27 guidance of ₹750 crore revenue with EBITDA margin around 17%, supported by long term contracts and a CDMO export ramp. Gross margin improved to 41.8% versus 38.1% in Q4 FY26, helped by price revisions that typically flow through with a 90 to 120 day lag. At the same time, EBITDA margin improvement was muted by elevated air freight costs in Australia as the group moved inventory by air to protect customer commitments during shipping disruptions.

Q1 FY27 performance in context

The company reported two sets of numbers. Standalone results reflected strong growth and operating leverage, while consolidated results were shaped by Noumed’s scale and cost base. Management’s commentary focused on the consolidated picture because it now represents the operating reality of the group.

One point that investors need to keep in mind is the shape of the business. Management stated that the year is expected to split 45:55 between the two halves, with the fourth quarter historically the strongest. That framing matters because Q1 performance is not intended to be extrapolated linearly.

Revenue engines and mix shift: from tenders to private and exports

Sai Parenterals describes itself as an integrated CDMO and branded generics enterprise, focused on injectables and oral dosage forms, with regulated and semi regulated markets becoming a larger part of the story.

In FY26, the company disclosed a sharp shift in business mix. CDMO products and services contributed 63% of FY26 net revenue and branded generic formulations contributed 37%. This is a meaningful change versus FY23, when CDMO was only 5% and branded formulations were 95%. The company also disclosed a channel shift away from institutional tenders. Private sector share rose from 39% in FY23 to 81% in FY26, while institutional share fell to 19%.

Exports became central to the growth narrative as well. Export share of revenue from operations rose from 3% in FY23 to 63% in FY26. Australia continued to anchor export revenue, contributing 76% of export revenue in FY26. The Philippines also featured prominently, supported by new CDMO and government contracts, including an exclusive anti tuberculosis contract valued at USD 11 million over four years from June 2026.

The group’s contracted visibility is anchored by long duration agreements. Noumed renewed an exclusive OTC supply agreement effective 1 July 2026, valued at AUD 202 million over 7.5 years, with a further 3 year option. On the earnings call, Noumed management clarified that new product development additions under that relationship are expected to be incremental to the stated contract value.

A capex heavy FY27, and a major change in how IPO proceeds are deployed

The biggest strategic announcement in this cycle is a proposed variation in the utilisation of IPO proceeds. Management’s message was consistent across the presentation and the call. The objective is unchanged, but the route has changed.

The company proposes to redeploy ₹101.85 crore of IPO proceeds into two acquisitions, subject to shareholder approval.

1. A 60% stake in Saicriti Pharma for ₹83.83 crore. Saicriti’s facility at Gummadidala outside the Hyderabad ORR is under construction and is intended to be built to EU GMP and USFDA standards. The company stated that this route delivers about 154.66 million units of injectable capacity, around 47% higher than the earlier plan to upgrade Units I and II from 57 million to 105 million units. Units I and II at Jeedimetla are expected to be discontinued on commissioning of the new facility.

2. A 60% stake in Prathyak Laboratories for ₹15 crore. Prathyak is described as an operating R and D centre at Genome Valley with 65 personnel including 28 research scientists and a pipeline of 150 SKUs across 86 molecules, with capabilities in complex injectables and oncology.

Management cited Hyderabad’s Industrial Lands Transformation Policy and a physical footprint constraint at Jeedimetla as key drivers for the change. The timeline impact, as disclosed, is limited. Completion of the new injectable facility is targeted for April 2027, about one month later than the original plan.

Australia: the pivot from distribution to manufacturing

Noumed sits at the center of the regulated market strategy. The business model described on the call is a registration led platform where Noumed holds marketing authorisations and supplies private label OTC and prescription products to pharmacy chains under long term exclusive agreements.

Today, Noumed sources much of its portfolio from third party manufacturers, which management said yields a distribution margin of about 10%. The Adelaide facility is intended to change that. Once the facility is commissioned, the group expects the same contracted revenue to be earned at a manufacturing margin rather than a distribution margin, while also reducing lead times and inventory intensity.

The company disclosed that the Adelaide programme is AUD 53 million, backed by an AUD 20 million Australian Government grant, with funding stated as complete. Management guided physical completion by January 2027, a TGA licensing inspection by March 2027, and Phase 1 manufacturing from April 2027.

What to watch from here

Management described FY27 as an execution focused year and FY28 as the inflection point as investments monetise. The roadmap is milestone heavy. Unit III expansion is expected to complete by October 2026, Unit IV EU GMP works by January 2027, Adelaide commissioning in early 2027, and the new injectable facility by April 2027.

The opportunity set is clear in the company’s own framing. Sai Parenterals wants to combine dossier depth, contracted demand, and a larger manufacturing base across India and Australia. But the practical bottleneck is accreditation and commissioning. The company explicitly stated it has no injectable export accreditation for the European Union today and expects accreditation within twelve months of physical completion of the new facility and the Unit IV upgrade.

The near term debate therefore is less about demand visibility, which is supported by multi year contracts, and more about execution quality across projects and the speed at which margin expansion from vertical integration can show up once Adelaide and the new injectables capacity come online.

Takeaways

Sai Parenterals is trying to build an end to end platform that moves from dossiers and registrations to manufacturing and last mile commercialisation, with Noumed providing regulated market access. Q1 FY27 showed stable operating progress and reiterated guidance, while also highlighting how external logistics disruptions can pressure margins.

The proposed redeployment of IPO proceeds is the key strategic pivot. If shareholder approvals and definitive agreements follow, the group will be betting on a larger injectable asset and an immediately productive R and D team, rather than a slower greenfield approach. The next twelve months will be judged by commissioning timelines and regulatory readiness, because the company’s own inflection narrative begins in FY28.